Combination

Phase 3Biologic

GSK

Combination is one of 138 biologic programs targeting Gingivitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

137

Competitors

Pipeline

Status by Indication[3][1]

Indication

GingivitisActive, not recruiting

Breast CancerActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

MigraineActive, not recruiting

COVID-19Active, not recruiting

Tobacco Use CessationNot yet recruiting

Sensorineural Hearing LossActive, not recruiting

GingivitisPreclinical

Active, not recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Rheumatoid ArthritisPhase 3

Active, not recruiting

MigrainePhase 3

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Tobacco Use CessationPreclinical

Not yet recruiting

Sensorineural Hearing LossPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Combination

GSK

Phase 3

1 2

Tecentriq

Roche

Preclinical

36 3

Tykerb

GSK

Preclinical

80 4

Prolia

Amgen

Preclinical

14 5

DATROWAY

Daiichi Sankyo

Preclinical

4 6

Megace

Bristol-Myers Squibb

Preclinical

4 7

Paracetamol

GSK

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 10

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

PreclinicalNot yet recruiting

Tobacco Use Cessation

NCT07693660

Clinical

Trials by Indication[1]

Migraine3 trials

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)

Completed· GSK logo

GSK·Phase 3·NCT00382993·169 enrolled

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)

Completed· GSK logo

GSK·Phase 3·NCT00383162·173 enrolled

TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine

Completed· GSK logo

GSK·Phase 3·NCT00385008·20 enrolled

Breast Cancer1 trial

Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)

Completed·FFuda Cancer Hospital, Guangzhou·Phase 1/2·NCT02418481·40 enrolled

Statin1 trial

The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease

Unknown status·SSamsung Medical Center·Phase 2·NCT02516826·504 enrolled

Hyaluronic Acid1 trial

The Effectiveness and Safety of Cleanser Containing Triethyl Citrate, Pyruvic Acid, Combination Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Salicylic Acid 0,5%, Zinc Lactate, Hyaluronic Acid and Spot Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Honokiol

Not yet recruiting·DDr.dr.Irma Bernadette, SpKK (K)·Phase 3·NCT06775314·102 enrolled

AIN1 trial

Effectivity and Safety of Combination of Spent Grain Wax, Argan Oil, Shea Butter and Saccharide Isomerate

Unknown status·DDr.dr.Irma Bernadette, SpKK (K)·Phase 1·NCT05186246·20 enrolled

9 more indications

Effectiveness1 trial

The Effectiveness of Herbal Creams Compared to Urea in Dry Skin Treatment

Completed·UUniversitas Syiah Kuala·Phase 1/2·NCT07360639·64 enrolled

Lip1 trial

Effectivity and Safety of Combination Cream of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad and Zinc PCA

Unknown status·DDr.dr.Irma Bernadette, SpKK (K)·Phase 1·NCT05497323·284 enrolled

Paclitaxel1 trial

S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC

Withdrawn· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 1/2·NCT05312372

Gingivitis1 trial

Comparisons Of Different Antiplaque Agents On Gingivitis In Orthodontic Patients

Completed·AAnam Sattar·N/A·NCT06305546·80 enrolled

Sensorineural Hearing Loss1 trial

Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus.

Completed·—·Phase 1·NCT06025097·70 enrolled

Photoaging1 trial

Effects of RF Microneedle on Photoaging Skin

Completed·—·N/A·NCT05710068·15 enrolled

COVID-191 trial

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

Completed· Pfizer logo

Pfizer·Phase 2·NCT05886777·1,142 enrolled

Rheumatoid Arthritis1 trial

Comparison of Three Different Treatment Regimes in Early Rheumatoid Arthritis: A Randomized Open-labelled Trial

Completed·—·Phase 3·NCT01870128·60 enrolled

Tobacco Use Cessation1 trial

Optimizing Pharmacist-Led Tobacco Treatment for Individuals Who Smoke and Are Not Ready to Make a Quit Attempt in Federally-Qualified Health Centers

Not yet recruiting·UUniversity of Virginia·Preclinical·NCT07693660·592 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Combination. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Combination compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Combination. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: GSK

Combination

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Migraine3 trials

Breast Cancer1 trial

Statin1 trial

Hyaluronic Acid1 trial

AIN1 trial

Effectiveness1 trial

Lip1 trial

Paclitaxel1 trial

Gingivitis1 trial

Sensorineural Hearing Loss1 trial

Photoaging1 trial

COVID-191 trial

Rheumatoid Arthritis1 trial

Tobacco Use Cessation1 trial

References

Drug Info

Quick Facts

Related News